Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 4,170 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Clear all
Not listed No phase listed Observational

Quality of Life Study for Prostate Cancer Patients

NCT00561444
View directory record Official record
Conditions
Prostate Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
1,051 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
3
States / cities
Voorhees Township, New Jersey • Albuquerque, New Mexico • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Not applicable Interventional

Developing Inclusive Support and Intervention for Spanish-speaking Latiné Prostate Cancer Survivors

NCT06435871
View directory record Official record
Conditions
Prostate Cancer
Interventions
Expanded Prostate Cancer Index Composite and Decision Regret Scale
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Phase 1Phase 2 Interventional

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

NCT04381832
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant
Interventions
Etrumadenant, Zimberelimab, Quemliclustat, Enzalutamide, Docetaxel, SG
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
17
States / cities
Cerritos, California • Encino, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 23, 2026, 4:18 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

NCT06085664
View directory record Official record
Conditions
Prostate Cancer, Radical Prostatectomy
Interventions
REGN5678, Piflufolastat F18
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 4:18 AM EDT
Terminated Phase 1 Interventional

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

NCT01174199
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
vorinostat, temsirolimus, laboratory biomarker analysis, positron emission tomography/computed tomography
Drug · Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer

NCT00972309
View directory record Official record
Conditions
Prostate Specific Antigens, Prostate Neoplasms
Interventions
T-cell receptor alternate reading frame protein (TARP) peptide vaccine, T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 23, 2026, 4:18 AM EDT
Terminated Phase 2 Interventional

Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer

NCT00521781
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Abraxane, Leuprolide, Bicalutamide
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 23, 2026, 4:18 AM EDT
Terminated Phase 2 Interventional Results available

Cabozantinib in Men With Castration-Resistant Prostate Cancer

NCT01703065
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Castration-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Cabozantinib
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 23, 2026, 4:18 AM EDT
Completed No phase listed Observational

Continuation of Follow-up of DES-Exposed Cohorts

NCT00340600
View directory record Official record
Conditions
Breast Cancer, Autoimmune Disease, Prostate Cancer, Ovarian Cancer, Endometrial Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
10,805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Not applicable Interventional

Long-Term Follow-Up in Patients With Prostate Cancer After Surgery

NCT03035500
View directory record Official record
Conditions
Cancer Survivor, Prostate Carcinoma
Interventions
Educational Intervention, Laboratory Biomarker Analysis, Long-term Follow-up, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Male only
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

NCT02854436
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Niraparib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Riverside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Phase 1 Interventional

Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate

NCT00459407
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer
Interventions
defined green tea catechin extract, placebo, immunohistochemistry staining method, immunoenzyme technique, laboratory biomarker analysis, biopsy, mass spectrometry, high performance liquid chromatography
Dietary Supplement · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Results available

Intensity Modulated Radiation Therapy (IMRT) Radiotherapy for Treating Prostate Pelvic Nodes

NCT00214136
View directory record Official record
Conditions
Prostate Cancer
Interventions
radiotherapy
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Phase 1Phase 2 Interventional

Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy

NCT01009736
View directory record Official record
Conditions
Prostate Cancer
Interventions
tomato-soy juice, laboratory biomarker analysis, pharmacological study, therapeutic conventional surgery
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 23, 2026, 4:18 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

NCT07258407
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostatic Cancer
Interventions
TD001
Drug
Lead sponsor
T.O.A.D. Oncology SA
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 23, 2026, 4:18 AM EDT
Active, not recruiting Early Phase 1 Interventional

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

NCT04147494
View directory record Official record
Conditions
Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Kidney Carcinoma, Lung Carcinoma, Ovarian Carcinoma, Pancreatic Carcinoma, Solid Neoplasm, Uterine Corpus Cancer
Interventions
Computed Tomography, Gallium Ga 68 FAPi-46, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography, 18F-FDG
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Not applicable Interventional Results available

PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy

NCT04843566
View directory record Official record
Conditions
Infection
Interventions
Transperineal MRI-guided prostate biopsy, Transrectal MRI-guided prostate biopsy, Antibiotic (prophylaxis)
Procedure · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Farmington, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 23, 2026, 4:18 AM EDT
Recruiting Phase 1 Interventional

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT06217822
View directory record Official record
Conditions
Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
Interventions
225Ac-PSMA-Trillium (BAY3563254)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
4
States / cities
Duarte, California • Minneapolis, Minnesota • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 23, 2026, 4:18 AM EDT
Terminated Not applicable Interventional

Acupuncture in Treating Hot Flashes in Patients With Prostate Cancer

NCT00244894
View directory record Official record
Conditions
Fatigue, Hot Flashes, Prostate Cancer
Interventions
acupuncture therapy, fatigue assessment and management, hot flashes attenuation, management of therapy complications, quality-of-life assessment
Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 23, 2026, 4:18 AM EDT
Withdrawn Phase 2 Interventional

Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer

NCT04020094
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
MVA-BN-Brachyury
Combination Product
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 23, 2026, 4:18 AM EDT
Not listed Early Phase 1 Interventional

Total Body PET-CT Imaging of Prostate Cancer Using Illuccix

NCT05558956
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
illuccix 68Ga-PSMA-11 Total Body PET-CT
Drug
Lead sponsor
BAMF Health
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

True NTH Sexual Recovery Intervention for Prostate Cancer Survivors and Their Partners

NCT02702453
View directory record Official record
Conditions
Sexual Disfunction, Prostate Cancer
Interventions
website
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Male only
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 23, 2026, 4:18 AM EDT
Active, not recruiting Not applicable Interventional

MRI Screening in Men at High Risk of Developing Prostate Cancer

NCT05608694
View directory record Official record
Conditions
Prostate Cancer Screening
Interventions
Prostate MRI
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2039
U.S. locations
2
States / cities
Chicago, Illinois • Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Phase 1 Interventional

Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors

NCT02144051
View directory record Official record
Conditions
Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
Interventions
AZD5312
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Sarasota, Florida • Nashville, Tennessee • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 23, 2026, 4:18 AM EDT